2.96 (-%)
As of Nov 01, 2024
Source:
We are a biopharmaceutical company with product candidates in pre-clinical and clinical development. We are principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimers disease (AD), which is in the clinical testing stage.
Country | United States |
Headquarters | new york, new york |
Phone Number | 9732420005 |
Industry | manufacturing |
CEO | Alan J. Tuchman |
Website | www.synaptogen.com |